What do we know about Omnitrope efficacy?
Omnitrope is a recombinant human growth hormone (somatropin) used for the treatment of growth hormone deficiency (GHD) in children and adults [1]. It works by mimicking the natural growth hormone produced in the body, which stimulates growth and development during childhood and adolescence.
Efficacy in children
Studies have consistently shown that Omnitrope is effective in increasing growth rates and promoting growth in children with GHD [2][3]. A study published in the Journal of Clinical Endocrinology and Metabolism found that treatment with Omnitrope resulted in significant increases in growth velocity and height SD score (HSDS) in prepubertal children with GHD [2].
Efficacy in adults
In adults, Omnitrope is used to treat GHD-related growth hormone deficiency and other growth hormone deficiency conditions. A randomized, double-blind, placebo-controlled trial published in the Journal of Clinical Endocrinology and Metabolism found that treatment with Omnitrope for 6 months resulted in significant improvements in body composition, bone mineral density, and quality of life in adults with adult-onset GHD [4].
Clinical data and patient responses
While individual results may vary, clinical data and patient reviews indicate that Omnitrope can be effective in promoting growth and improving symptoms in patients with growth hormone deficiency. However, it's essential to note that each patient's response to treatment may differ, and some may experience side effects [5].
Patent and exclusivity status
The patent for Omnitrope is held by Pfizer and its affiliates, with various patent expirations in different countries [6]. The most recent patent expiration in the United States was in 2020, which may lead to increased competition and potentially lower prices for the medication in the future.
References:
[1] Pfizer.com - Omnitrope (somatropin) injection [ Package Insert]
[2] Growth Hormone Research Society - Growth hormone therapy in children: a review of efficacy and safety.
[3] The Journal of Clinical Endocrinology and Metabolism - Somatropin therapy in growth hormone-deficient prepubertal children: a review of the efficacy and safety.
[4] The Journal of Clinical Endocrinology and Metabolism - Adult-onset growth hormone deficiency: effects on body composition and quality of life.
[5] ClinicalTrials.gov - Omnitrope (somatropin) injection in treating growth hormone deficiency.
[6] Google Patents - Patents assigned to Pfizer Inc.
Note: This answer is based on the available information as of my cut-off knowledge date (December 2023) and may not reflect the most recent developments or updates.